IPSC
Century Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$2.19-2.67%
Price as of Jul 20, 2026
IPSC growth
Century Therapeutics, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- -100.0%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- +16.3%
- Operating cash flow
- +17.5%
Forward estimates
- Revenue
- —
- EBITDA
- +99.4%
- EPS
- +74.1%
Three-year CAGR
- Revenue
- +175.9%
- EBITDA
- +103.1%
- EBIT
- +89.1%
- Net income
- +92.4%
- EPS
- +93.2%
- Free cash flow
- +5.0%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.